Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
By M. Vaswani, Farzana Kadar Linda, S. Ramesh. Progress in Neuro-psychopharmacology and Biological Psychiatry, 2003
620 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/6782209637fd0bd91430cecd62709cf9ad2a7c6c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
In Pharmacology
- Michael T. Treadway
- David H. Zald
- Ted G. Dinan
- G. Clarke
- Mercè Correa
- John Salamone
- Kent C. Berridge
Citations in the corpus
- Identification of an allosteric modulator of the serotonin transporter with novel mechanism of action. (2013, background): “hSERT inhibitors, including the SSRIs, are used for treating mood disorders and anxiety (Vaswani et al., 2003).”
- Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. (2005, background): “…reuptake inhibitors (SSRIs), is effective in anxiety disorders (Argyropoulos et al., 2000; Millan, 2003; Vaswani et al., 2003) has stimulated researchers to develop anxiolytics that influence the serotonin and/or noradrenergic systems (Kent et al., 2002; Gorman, 2003; Vaswani et al., 2003).”
- Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “The 5-HT system is undoubtedly one of the most studied neurotransmitter systems in depression, and SSRIs are the most widely prescribed antidepressant medication (Masand and Gupta, 1999, Vaswani et al., 2003).”
- The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. (2008, background): “The side-effect profiles of these earlier treatments have significantly improved with the introduction of the selective serotonin re-uptake inhibitors (Vaswani et al., 2003), and the more recent emergence of the serotonin and noradrenaline re-uptake inhibitors (Papakostas et al., 2007).”
- Reconsidering Anhedonia in Depression: Lessons from Translational Neuroscience (2010, background): “Additionally, it is worth noting that these medications may be more effective in treating the anxiogenic aspects of depression, as suggested by their efficacy in the treatment of anxiety disorders (Davis et al., 2006; Ninan, 2003; Sheehan and Mao, 2003; Vaswani et al., 2003).”